Active, not recruitingPHASE2, PHASE3NCT05522231
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hutchmed
- Principal Investigator
- Dingwei YeFudan University
- Intervention
- fruquintinib+sintilimab(drug)
- Enrollment
- 265 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2022 – 2025
Study locations (30)
- Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
- Peking Union Medical College Hospital, Beijing, China
- Peking University First Hospital, Beijing, China
- Peking University Third Hospital, Beijing, China
- The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
- The First Hospital of Jilin University, Changchun, China
- Hunan Cancer Hospital, Changsha, China
- Xiangya Hospital Central South University, Changsha, China
- Sichuan Provincial People's Hospital, Chengdu, China
- West China Hospital of Sichuan University, Chengdu, China
- Chongqing University Cancer Hospital, Chongqing, China
- The First Affilated Hospital of Fujian Medical University, Fuzhou, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
- Sun Yat-sen University Cancer Center, Guangzhou, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05522231 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →